Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEXCOM INC Director's Dealing 2018

Mar 12, 2018

30198_dirs_2018-03-12_79ce320e-cf64-49c2-8a18-ec2fcd4dad2a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2018-03-08

Reporting Person: Abbey Donald (EVP, Quality & Regulatory Afrs)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-03-08 Common Stock A 38502 $0.001 Acquired 113228 Direct

Footnotes

F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2: Included in this number are 93,508 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 18,340 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 36,666 of which were granted on May 31, 2016 and shall vest through May 31, 2019.